BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29798825)

  • 1. Development of autotaxin inhibitors: A series of zinc binding triazoles.
    Thomson CG; Le Grand D; Dowling M; Brocklehurst CE; Chinn C; Elphick L; Faller M; Freeman M; Furminger V; Gasser C; Hamadi A; Hardaker E; Head V; Hill JC; Janus DI; Pearce D; Poulaud AS; Stanley E; Sviridenko L
    Bioorg Med Chem Lett; 2018 Jul; 28(13):2279-2284. PubMed ID: 29798825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
    Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
    Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PF-8380 and closely related analogs: synthesis and structure-activity relationship towards autotaxin inhibition and glioma cell viability.
    St-Cœur PD; Ferguson D; Morin P; Touaibia M
    Arch Pharm (Weinheim); 2013 Feb; 346(2):91-7. PubMed ID: 23300119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors.
    Joncour A; Desroy N; Housseman C; Bock X; Bienvenu N; Cherel L; Labeguere V; Peixoto C; Annoot D; Lepissier L; Heiermann J; Hengeveld WJ; Pilzak G; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Galien R; David C; Vandervoort N; Christophe T; Conrath K; Jans M; Wohlkonig A; Soror S; Steyaert J; Touitou R; Fleury D; Vercheval L; Mollat P; Triballeau N; van der Aar E; Brys R; Heckmann B
    J Med Chem; 2017 Sep; 60(17):7371-7392. PubMed ID: 28731719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
    Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J
    J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of autotaxin inhibitors: A series of tetrazole cinnamides.
    Thomson CG; Le Grand D; Dowling M; Beattie D; Elphick L; Faller M; Freeman M; Hardaker E; Head V; Hemmig R; Hill J; Lister A; Pascoe D; Rieffel S; Shrestha B; Steward O; Zink F
    Bioorg Med Chem Lett; 2021 Jan; 31():127663. PubMed ID: 33160025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autotaxin inhibitors: a patent review (2012-2016).
    Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
    Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based discovery of (S)-2-amino-6-(4-fluorobenzyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione as low nanomolar, orally bioavailable autotaxin inhibitor.
    Roy A; Sarkar T; Datta S; Maiti A; Chakrabarti M; Mondal T; Mondal C; Banerjee A; Roy S; Mukherjee S; Muley P; Chakraborty S; Banerjee M; Kundu M; Roy KK
    Chem Biol Drug Des; 2022 Mar; 99(3):496-503. PubMed ID: 34951520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and optimization of ATX inhibitors via modeling, synthesis and biological evaluation.
    Balupuri A; Lee MH; Chae S; Jung E; Yoon W; Kim Y; Son SJ; Ryu J; Kang DH; Yang YJ; You JN; Kwon H; Jeong JW; Koo TS; Lee DY; Kang NS
    Eur J Med Chem; 2018 Mar; 148():397-409. PubMed ID: 29477073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model.
    Nikolaou A; Ninou I; Kokotou MG; Kaffe E; Afantitis A; Aidinis V; Kokotos G
    J Med Chem; 2018 Apr; 61(8):3697-3711. PubMed ID: 29620892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autotaxin inhibitors: a patent review.
    Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
    Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A.
    Burdi DF; Campbell JE; Wang J; Zhao S; Zhong H; Wei J; Campbell U; Shao L; Herman L; Koch P; Jones PG; Hewitt MC
    Bioorg Med Chem Lett; 2015 May; 25(9):1864-8. PubMed ID: 25863433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis.
    Baader M; Bretschneider T; Broermann A; Rippmann JF; Stierstorfer B; Kuttruff CA; Mark M
    Br J Pharmacol; 2018 Feb; 175(4):693-707. PubMed ID: 29197066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of autotaxin alleviates inflammation and increases the expression of sodium-dependent glucose cotransporter 1 and Na
    He P; Haque A; Lin S; Cominelli F; Yun CC
    Am J Physiol Gastrointest Liver Physiol; 2018 Nov; 315(5):G762-G771. PubMed ID: 30118349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Bulk of Autotaxin Activity Is Dispensable for Adult Mouse Life.
    Katsifa A; Kaffe E; Nikolaidou-Katsaridou N; Economides AN; Newbigging S; McKerlie C; Aidinis V
    PLoS One; 2015; 10(11):e0143083. PubMed ID: 26569406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
    Malamas MS; Ni Y; Erdei J; Stange H; Schindler R; Lankau HJ; Grunwald C; Fan KY; Parris K; Langen B; Egerland U; Hage T; Marquis KL; Grauer S; Brennan J; Navarra R; Graf R; Harrison BL; Robichaud A; Kronbach T; Pangalos MN; Hoefgen N; Brandon NJ
    J Med Chem; 2011 Nov; 54(21):7621-38. PubMed ID: 21988093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.
    Cuozzo JW; Clark MA; Keefe AD; Kohlmann A; Mulvihill M; Ni H; Renzetti LM; Resnicow DI; Ruebsam F; Sigel EA; Thomson HA; Wang C; Xie Z; Zhang Y
    J Med Chem; 2020 Jul; 63(14):7840-7856. PubMed ID: 32584034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of 2,4-dihydropyrano[2,3-c]pyrazole derivatives as autotaxin inhibitors.
    Pantsar T; Singha P; Nevalainen TJ; Koshevoy I; Leppänen J; Poso A; Niskanen JMA; Pasonen-Seppänen S; Savinainen JR; Laitinen T; Laitinen JT
    Eur J Pharm Sci; 2017 Sep; 107():97-111. PubMed ID: 28687529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and pharmacological characterization of a novel inhibitor of autotaxin in rodent models of joint pain.
    Thirunavukkarasu K; Swearingen CA; Oskins JL; Lin C; Bui HH; Jones SB; Pfeifer LA; Norman BH; Mitchell PG; Chambers MG
    Osteoarthritis Cartilage; 2017 Jun; 25(6):935-942. PubMed ID: 27638130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.
    Bain G; Shannon KE; Huang F; Darlington J; Goulet L; Prodanovich P; Ma GL; Santini AM; Stein AJ; Lonergan D; King CD; Calderon I; Lai A; Hutchinson JH; Evans JF
    J Pharmacol Exp Ther; 2017 Jan; 360(1):1-13. PubMed ID: 27754931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.